Ultrasound tumour treatment developer HistoSonics has been backed by Michigan’s Mints initiative and student-run Wolverine Venture Fund.

HistoSonics, a US-based ultrasound tumour treatment developer based on University of Michigan research, today raised an initial $8.3m in series B funding from investors including the university’s Michigan Investment in New Technology Startups (Mints) program.
The round was led by VC firm Venture Investors and backed by University of Michigan’s student-run Wolverine Venture Fund, as well as Fletcher Spaght Ventures, the investment arm of strategic consultancy Fletcher Spaght.
VC firm Hatteras Venture Partners also took part in the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?